Altered Protein Expression of Cardiac CYP2J and Hepatic CYP2C, CYP4A, and CYP4F in a Mouse Model of Type II Diabetes—A Link in the Onset and Development of Cardiovascular Disease?
Open Access
- 12 October 2017
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 9 (4), 44
- https://doi.org/10.3390/pharmaceutics9040044
Abstract
Arachidonic acid can be metabolized by cytochrome P450 (CYP450) enzymes in a tissue- and cell-specific manner to generate vasoactive products such as epoxyeicosatrienoic acids (EETs-cardioprotective) and hydroxyeicosatetraenoic acids (HETEs-cardiotoxic). Type II diabetes is a well-recognized risk factor for developing cardiovascular disease. A mouse model of Type II diabetes (C57BLKS/J-db/db) was used. After sacrifice, livers and hearts were collected, washed, and snap frozen. Total proteins were extracted. Western blots were performed to assess cardiac CYP2J and hepatic CYP2C, CYP4A, and CYP4F protein expression, respectively. Significant decreases in relative protein expression of cardiac CYP2J and hepatic CYP2C were observed in Type II diabetes animals compared to controls (CYP2J: 0.80 ± 0.03 vs. 1.05 ± 0.06, n = 20, p < 0.001); (CYP2C: 1.56 ± 0.17 vs. 2.21 ± 0.19, n = 19, p < 0.01). In contrast, significant increases in relative protein expression of both hepatic CYP4A and CYP4F were noted in Type II diabetes mice compared to controls (CYP4A: 1.06 ± 0.09 vs. 0.18 ± 0.01, n = 19, p < 0.001); (CYP4F: 2.53 ± 0.22 vs. 1.10 ± 0.07, n = 19, p < 0.001). These alterations induced by Type II diabetes in the endogenous pathway (CYP450) of arachidonic acid metabolism may increase the risk for cardiovascular disease by disrupting the fine equilibrium between cardioprotective (CYP2J/CYP2C-generated) and cardiotoxic (CYP4A/CYP4F-generated) metabolites of arachidonic acid.This publication has 41 references indexed in Scilit:
- Cytochrome P450-derived eicosanoids and heart functionPharmacology & Therapeutics, 2017
- The endothelial cyclooxygenase pathway: Insights from mouse arteriesEuropean Journal of Pharmacology, 2016
- Mammalian lipoxygenases and their biological relevanceBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2015
- Lipids as targets for novel anti-inflammatory therapiesPharmacology & Therapeutics, 2009
- Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiologyExpert Opinion on Drug Metabolism & Toxicology, 2009
- Eicosanoid signalling pathways in the heartCardiovascular Research, 2008
- Epoxyeicosatrienoic acids, cell signaling and angiogenesisProstaglandins & Other Lipid Mediators, 2007
- Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injuryProstaglandins & Other Lipid Mediators, 2007
- Detection of Human CYP2C8, CYP2C9, and CYP2J2 in Cardiovascular TissuesDrug Metabolism and Disposition, 2007
- Involvement of CYP3A‐derived arachidonic acid metabolite(s) in responses to endothelium‐derived K+ channel opening substance in monkey lingual arteryBritish Journal of Pharmacology, 1999